Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
| Image |  |
|---|---|
| Description | scientific article published on 30 August 2018 |
| Author/s |
author: Zuzana Tatar Bruno Pereira Anne Tournadre Jean-Jacques Dubost Martin Soubrier |
| Publication date | August 30, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |